Σχόλιο: προστέθηκε το %subject., 23/11/2011 - 23:00
Ιατρικού ενδιαφέροντος άρθρο για την πρόληψη του καρκίνου των ωοθηκών από την ιατρό Μελίνα Σιώνη, η οποία διαπρέπει αυτή τη στιγμή στις Ηνωμένες Πολιτείες. Η κυρία Σιώνη είναι γνώριμη του Βορειοηπειρωτικού χώρου, στέλεχος της προηγούμενης γενιάς της Νεολαίας Βορειοηπειρωτών ΝΕΒ,
μέλος της τότε κλειστής ομάδας Σέλιου-Μπολάνου-Κατσαλίδα.
Η ΝεΒ αποτελεί ίσως την πιο σταθερή οργάνωση στο "πολυτάραχο" Βορειοηπειρωτικό φάσμα, που άντεξε στον χρόνο. Εκκολαπτήριο στελεχών από το 2003, κάτι που δεν κατάφεραν τα Β/ηπειρωτικά κόμματα μέχρι και σήμερα.
Ευχόμαστε καλή σταδιοδρομία στην κα. Σιώνη πλούσια σε επιτυχίες!
(Ακολουθεί το αγγλικό κείμενο που μας εστάλη από τον κ. Δημήτριο Κούτουλα, πρόεδρο της Πανηπειρωτικής Ομοσπονδίας Αμερικής.)
INVEST IN EARLY DETECTION FOR OVARIAN CANCER
Melina Shoni, MD
Worldwide, the estimated annual incidence of ovarian cancer is 204,000 with 125,000 deaths. Ovarian cancer still keeps the highest fatality-to-case ratio of all gynecologic diseases. The lack of early detection strategies makes ovarian cancer particularly lethal. As most of the patients are diagnosed in advanced stage and 80% of them recur despite advancements in novel therapeutics, the 5-year survival rate is only 30%. This, specific and sensitive screening programs that reveal the disease at an early stage are of paramount value in preventing and treating this disease.
The association between autoimmunity and cancer is well established. Our innovative hypothesis is that serum autoantibodies, identified by the employment of a high-density microarray, can serve as cancer bio-markers. Not only will the dominant autoantibody profile provide us with invaluable screening tools for the early detection of ovarian cancer, but it may also help us elucidate the role of significant disease-related biochemical pathways. Components of those pathways may have promising translational relevance by being exploited as potential targets for novel therapies or monitors of treatment response and disease recurrence.
Q. Why did you want to become a medical researcher? Well, I strongly believe that medical research is inseparable from clinical practice: it keeps you on track providing deeper understanding of your objectives, it gives you the chance to generate new knowledge by elucidating the underlying components of several medical issues and of course it enlarges the benefit to mankind.
Q. Why did you choose to focus on cancer prevention? It has been shown that at least one-third of all cancer cases are preventable and ovarian cancer statistics speak for themselves: when ovarian cancer is diagnosed at an early stage, five-year survival rate exceeds 90% in contrast to less than 30% for patients with distant metastases. Effective secondary prevention can reverse the existing scene providing the most cost-effective long-term strategy for the disease control...and this is actually our goal.
Q. What is the one thing you would like people to know about this current research project? Our project investigates ovarian cancer from an immunologic perspective; three basic components account for its increased potentials in achieving our ultimate goal that is the identification of novel biomarkers for early ovarian cancer detection: our innovative approach, the large number of samples that will undergo autoantibody profiling and the very careful selection of all those cases so that we can identify the changes during the early stages of cancer development.
Q. How does the thought of preventing cancer make you feel? My feelings relate to the million of patients that have suffered, are suffering or will suffer from this disease but not to cancer itself...We will definitely continue the fight by all the available means...however, what we need to realize is that prevention will help us impose our own rules before the fight starts!
Αναδημοσίευση απο : borioipirotika.blogspot
